Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

The conversation is about using a DIY topical Cetirizine 1% solution with microneedling for hair loss treatment. Concerns were raised about potential side effects and the effectiveness of Cetirizine for this purpose.

Stem cell-related treatments and drugs like RCGD423 and WAY are being tested for hair growth. Clinics are conducting tests on patients who haven't had previous treatments.

The conversation humorously discusses hair loss treatments, mentioning Minoxidil, finasteride, and RU58841. It jokingly credits a person for the potential success of a treatment called GT20029.

A user discusses using tazarotene to enhance minoxidil's effectiveness for hair regrowth, believing it will make a significant difference. Others caution about potential risks of retinoids accelerating hair loss in some individuals.

The user has been using topical minoxidil for over a year and added kx826/pyrilutamide to improve hair growth, avoiding finasteride due to side effects like lowered libido and panic attacks. They report positive results with reduced shedding and healthier hair, particularly in areas previously unresponsive to minoxidil.

A 47-year-old male started using Minoxidil, Finasteride, Nizoral, Dermapen, and vitamins after his hair transplant was postponed due to COVID-19. He reported positive progress in hair growth over eight weeks with this routine.

Adipose-derived stem cells with ATP improved hair regrowth in male and female mice with androgenetic alopecia. The most effective treatments were low dose stem cells with ATP for males and medium dose stem cells with non-liposomal ATP for females.

Scientists discover SCUBE3 molecule for potential baldness cure. Mice used in research for hair growth signaling.

Balding scalps have more androgen receptors, leading to increased TGF-beta, which causes blood vessel loss and hair follicle miniaturization. Blocking androgen signaling and TGF-beta may help prevent hair loss.

The conversation discusses the results of a group buy for Ky19382 related to hair loss treatments. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

The user shared progress pictures showing significant hair regrowth after 8 months using finasteride and Minoxidil foam. They have not used microneedling and are considering oral Minoxidil but currently use topical Minoxidil and oral finasteride.

RU58841 may pose cancer risks due to its antiandrogen properties and lack of long-term safety data. Using it is considered a high-risk experiment with unknown potential for harm.

SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.

A user experienced excessive hair shedding after taking 17 mg of Zinc gluconate daily for acne. They are seeking advice on similar experiences and solutions.

GHK-Cu is a potent inhibitor of the type 1 5-alpha reductase enzyme in hair follicles, which may reduce hair loss without the side effects associated with type 2 5-alpha reductase inhibitors. The user previously experienced side effects with 5-alpha reductase inhibitors and is considering GHK-Cu as an alternative.

The user is seeking alternative hair loss treatments due to side effects from finasteride and minoxidil. They are inquiring about the availability of gt20029 from u-lab.

GHK-RU58841 is used for hair loss, with positive results when combined with finasteride, stemoxydine, redensyl, and alfatradiol. Users report effectiveness after adding finasteride.

The user experienced new hair growth after switching from oral finasteride to topical RU58841 with minoxidil and undergoing stem cell therapy. They noticed new hairs at the hairline and temples, but are unsure which treatment is responsible.

The conversation discusses potential advancements in two hair loss drugs, KX-826 and GT20029, and the interest in whether transitioning from oral finasteride to these drugs would maintain hair growth. One reply expresses skepticism about the compounds' representation.

GT20029 is discussed as a potential treatment for androgenetic hair loss by targeting androgen receptors, unlike finasteride which reduces DHT broadly. Concerns include its effectiveness, genetic variations in androgen receptors, and availability, with some skepticism about its potential as a true alternative.

The conversation is about the difficulty in obtaining GT20029, a hair loss treatment, due to patent issues and the need to resort to group buys or Chinese labs for acquisition. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

The user is experiencing irritation from using PG with RU58841 and is seeking alternative solutions like K&B in the UK. They report redness, itchiness, and flaky skin from the current treatment.

Hair loss treatment progress after 8 months using finasteride, minoxidil, nizoral, and dermarolling. Discussion includes positive feedback on results and question about needle replacement for dermarolling.

AHK and GHK are discussed for hair growth in the crown area, with questions about side effects and safety after microneedling. Users share experiences and concerns about these treatments.

Dr. Tsuji and Riken announced a hair cloning cure with a 98.9% success rate, expected to be released in 10 years. Users expressed hope and skepticism about the affordability and timeline of the treatment.

A 29-year-old male experienced significant hair regrowth over 8 months using a protocol of oral Minoxidil, Dutasteride, Pyrithione Zinc Shampoo, and peptides GHK-CU, BPC-157, and TB-500. The treatment led to improved scalp coverage, reduced hair loss, and thicker hair, although results may vary for others.

Cetirizine 1% cream significantly improves hair growth and thickness in men with androgenic alopecia. It is considered effective, affordable, and has a low side effect profile.